Step 3 The Deception: In the best case scenario, customers receive actual product, but its of questionable quality and effectiveness
Certain GLP-1 formulations have demonstrated cardiovascular benefits in clinical trials, leading to specific FDA approvals: Victoza, Ozempic, and Trulicity are approved for reducing major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, while Wegovy is approved for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight
But the brand-name versions made by a handful of pharmaceutical companies can be pricey, with Novo Nordisk's Wegovy costing about $1,350 a month, or more than $16,00 a year, without insurance, according to GoodRx
Multi-arm or multi-timepoint designs that would otherwise draw across several 10mg batches can run against a single 20mg batch and a single purity figure, removing inter-batch variance as a confounder
Chronic co-administration of bezafibrate with the GLP-1 analogue exendin-4, but not with the GIP receptor (GIPR) agonist [d-Ala 2 ]GIP(130) (D-GIP), enhanced the glucose-lowering effect of exendin-4 in db/db mice, and this was associated with improved islet morphology and increased beta cell mass and proliferation
